KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Rigel Pharmaceuticals (RIGL) over the last 14 years, with Q3 2025 value amounting to $17.3 million.

  • Rigel Pharmaceuticals' Non-cash Items rose 4416.67% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 4416.67%. This contributed to the annual value of $10.6 million for FY2024, which is 0.0% changed from last year.
  • Rigel Pharmaceuticals' Non-cash Items amounted to $17.3 million in Q3 2025, which was up 4416.67% from $20.5 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Non-cash Items ranged from a high of $23.2 million in Q1 2025 and a low of $1.6 million during Q4 2022
  • Over the past 5 years, Rigel Pharmaceuticals' median Non-cash Items value was $15.8 million (recorded in 2022), while the average stood at $14.8 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first tumbled by 7643.86% in 2022, then skyrocketed by 56043.61% in 2023.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Non-cash Items stood at $6.8 million in 2021, then plummeted by 76.44% to $1.6 million in 2022, then surged by 560.44% to $10.6 million in 2023, then changed by 0.0% to $10.6 million in 2024, then surged by 63.21% to $17.3 million in 2025.
  • Its last three reported values are $17.3 million in Q3 2025, $20.5 million for Q2 2025, and $23.2 million during Q1 2025.